Exegenesis Bio is a multinational company advancing innovative gene and cell therapies focused on three initial areas: central nervous system (CNS), ophthalmology and liver. To advance therapies in these areas, Exegenesis is using their proprietary discovery and manufacturing platforms including AAVarta®, an in-silico evolution discovery platform to design novel AAV capsids using AI technologies. Other platforms include Constellation®, an AI aided gene expression cassette design platform and Progress®, a data-driven protein engineering platform. Together, Exegenesis is advancing a diverse pipeline with lead programs for Spinal Muscular Atrophy and Age-Related Macular Degeneration in early stage clinical trials.

Exegenesis Bio

Founded: 2019
Location: Lower Gwynedd, PA
Employee range: 50 - 200
Clinical stage: Clin1
Therapy area: neovascular AMD
Drug types: GEN, MUS, NEU, OPH, GER, HEM, PED
Lead product: EXG102-031
Funding: $50M Jun 2021 ($120M total)

Drug notes:

About:

Jobs: